WO2008119571A3 - Nucleic acid myostatin antagonist aptamers obtained by (mirror- image) selex - Google Patents

Nucleic acid myostatin antagonist aptamers obtained by (mirror- image) selex Download PDF

Info

Publication number
WO2008119571A3
WO2008119571A3 PCT/EP2008/050046 EP2008050046W WO2008119571A3 WO 2008119571 A3 WO2008119571 A3 WO 2008119571A3 EP 2008050046 W EP2008050046 W EP 2008050046W WO 2008119571 A3 WO2008119571 A3 WO 2008119571A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
selex
mirror
image
myostatin antagonist
Prior art date
Application number
PCT/EP2008/050046
Other languages
French (fr)
Other versions
WO2008119571A2 (en
Inventor
Jens Rosengren Daugaard
Henning Thoegersen
Claus Bekker Jeppesen
Jesper Lau
Original Assignee
Novo Nordisk As
Jens Rosengren Daugaard
Henning Thoegersen
Claus Bekker Jeppesen
Jesper Lau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Jens Rosengren Daugaard, Henning Thoegersen, Claus Bekker Jeppesen, Jesper Lau filed Critical Novo Nordisk As
Publication of WO2008119571A2 publication Critical patent/WO2008119571A2/en
Publication of WO2008119571A3 publication Critical patent/WO2008119571A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Abstract

Myostatin antagonists are used to treat muscular generative disorders, type 2 diabetes or obesity. The antanogists are nucleic acid molecules capable of binding to myostatin.
PCT/EP2008/050046 2007-01-03 2008-01-03 Nucleic acid myostatin antagonist aptamers obtained by (mirror- image) selex WO2008119571A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07100067.3 2007-01-03
EP07100067 2007-01-03

Publications (2)

Publication Number Publication Date
WO2008119571A2 WO2008119571A2 (en) 2008-10-09
WO2008119571A3 true WO2008119571A3 (en) 2009-07-23

Family

ID=39587933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/050046 WO2008119571A2 (en) 2007-01-03 2008-01-03 Nucleic acid myostatin antagonist aptamers obtained by (mirror- image) selex

Country Status (1)

Country Link
WO (1) WO2008119571A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130414A1 (en) * 2015-02-09 2016-08-18 Somalogic, Inc. Nucleic acid compounds for binding growth differentiation factor 8

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008856A2 (en) * 1996-08-30 1998-03-05 Fuerste Jens Peter Mirror-symmetrical selection and evolution of nucleic acids
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20060251632A1 (en) * 2005-05-04 2006-11-09 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008856A2 (en) * 1996-08-30 1998-03-05 Fuerste Jens Peter Mirror-symmetrical selection and evolution of nucleic acids
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20060251632A1 (en) * 2005-05-04 2006-11-09 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BISHOP AMY ET AL: "The therapeutic potential of agents that inactivate myostatin.", EXPERT OPINION ON INVESTIGATIONAL DRUGS SEP 2005, vol. 14, no. 9, September 2005 (2005-09-01), pages 1099 - 1106, XP002524705, ISSN: 1744-7658 *
DATABASE UniProt [online] 12 December 2006 (2006-12-12), "GDF-8", XP002524706, retrieved from EBI accession no. UniProt:O14793 Database accession no. O14793 *
ULRICH HENNING ET AL: "DNA and RNA aptamers: from tools for basic research towards therapeutic applications", COMBINATORIAL CHEMISTRY AND HIGH THROUGHPUT SCREENING, BENTHAM SCIENCE PUBLISHERS, NL, vol. 9, no. 8, 1 September 2006 (2006-09-01), pages 619 - 632, XP008100029, ISSN: 1386-2073 *

Also Published As

Publication number Publication date
WO2008119571A2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
LTPA2019504I1 (en) Improved TM nanoparticles for the treatment of disorders caused by aggregation
IL243178A0 (en) Double-stranded ribonucleic acids (dsrna) for inhibiting expression of transthyretin (ttr), pharmaceutical compositions comprising them and use thereof in the treatment of disorders mediated by ttr expression
WO2009043889A3 (en) Oxadiazole derivatives
WO2007124424A3 (en) Il-8 receptor antagonists
WO2009052431A3 (en) Cd19 binding agents and uses thereof
WO2007104789A3 (en) Amylin derivatives
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
WO2010151799A3 (en) Compounds for modulating rna binding proteins and uses therefor
WO2007109211A3 (en) 1-oxo-isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2006083491A3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2008030367A3 (en) Selective myostatin inhibitors
WO2009043353A3 (en) Micromirs
WO2007150016A3 (en) Il-8 receptor antagonist
WO2010151797A3 (en) Compounds for modulating rna binding proteins and uses therefor
CL2007003049A1 (en) COMPOUNDS DERIVED FROM 2,4-DIAMINOPIRIMIDINE; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT PROLIFERATIVE DISORDERS.
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
MX2010008688A (en) Engineered anti-tslpr antibodies.
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
WO2009133573A3 (en) A homeopathic formulation
WO2007124423A3 (en) Il-8 receptor antagonists
WO2007022385A3 (en) Use of cxcr4 binding molecules for the treatment of whim syndrome
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
WO2008113515A3 (en) huTNFR1 SELECTIVE ANTAGONISTS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08701228

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08701228

Country of ref document: EP

Kind code of ref document: A2